Charcot Foot

01Pathophysiology

Charcot neuroarthropathy is fundamentally a disease of uncontrolled inflammation in a foot that has lost its protective pain feedback. The underlying mechanism begins with peripheral neuropathy, most often from long-standing, poorly controlled diabetes. When sensory nerves are destroyed, the patient loses the ability to perceive microtrauma, repetitive stress, and even frank fractures.

There are two classic theories that explain the joint destruction, and both likely contribute simultaneously. The neurotraumatic theory states that the insensate foot sustains repetitive mechanical injury during normal walking, leading to microfractures that go unrecognized. Because the patient feels no pain, they continue to ambulate, causing progressive skeletal damage. The neurovascular theory proposes that autonomic neuropathy leads to loss of sympathetic vascular tone in the foot, causing increased arterial blood flow, bony hyperemia, and accelerated osteoclastic resorption. This combination of increased blood flow and ongoing mechanical stress creates a vicious cycle of bone weakening, fracture, and further destruction.

Once an initial insult occurs (a minor sprain, a stress fracture, or even surgery), the inflammatory cascade is activated. Pro-inflammatory cytokines such as TNF-alpha and IL-1 upregulate the RANKL/OPG pathway, promoting excessive osteoclast activity and bone resorption. In a sensate patient, the resulting pain would force immobilization, limiting the damage. In the neuropathic patient, the absence of pain means continued weight-bearing, which perpetuates the inflammatory cycle.

The midfoot (tarsometatarsal joints, also known as the Lisfranc complex) is the most commonly affected site, accounting for roughly 60% of cases. This is why the classic deformity is a "rocker-bottom" foot: the midfoot arch collapses downward due to fracture-dislocation and ligament destruction. The resulting bony prominences on the plantar surface create abnormal pressure points, which then lead to skin breakdown and ulceration, a portal for secondary infection.

This is why Charcot foot is so dangerous in a clinical vignette: a seemingly stable ambulatory diabetic patient with a warm, swollen, painless foot is actually experiencing progressive skeletal destruction.

02Classification and Clinical Manifestation

The most frequently tested classification system is the Eichenholtz staging system, which describes the radiographic and clinical progression of the disease.

Anatomic classification (Sanders and Frykberg) describes location patterns:

Pattern II (midfoot, Lisfranc joint) is the highest-yield location for exam questions because it produces the classic rocker-bottom deformity.

03Diagnostic Workup

The best initial imaging test is weight-bearing radiographs of the affected foot. In a vignette presenting a diabetic patient with a warm, swollen, painless foot, the first step in the workup is obtaining plain films. In later stages, the findings are dramatic and unmistakable: fracture-dislocations, bony fragmentation, and architectural collapse. However, in Stage 0 (the prodromal phase), radiographs are completely normal.

MRI is the most sensitive and most accurate test for early disease detection. When clinical suspicion is high (warm, neuropathic foot) but radiographs are normal, MRI should be ordered. It reveals bone marrow edema and subclinical fractures that precede visible bony destruction. MRI is also essential when the question is whether the patient has Charcot neuroarthropathy or osteomyelitis, a distinction that is heavily tested.

The key differentiating point between Charcot foot and osteomyelitis on MRI is the distribution of bone marrow edema: Charcot typically involves multiple joints in a periarticular pattern, whereas osteomyelitis tends to be focal and contiguous with an overlying ulcer. The presence of a sinus tract extending from a skin ulcer to bone on MRI strongly favors osteomyelitis.

When MRI is inconclusive, a combined triple-phase bone scan (Tc-99m) with a tagged WBC scan (In-111) can help. In pure Charcot, the bone scan is hot (increased metabolic activity) but the WBC scan is cold (no infection). In osteomyelitis, both scans are hot.

Laboratory values are used primarily to exclude infection. An elevated WBC count, ESR > 70 mm/hr, or CRP significantly above baseline in a Charcot patient with an overlying ulcer should prompt further investigation for osteomyelitis. A probe-to-bone test through an open ulcer that contacts bone has a high positive predictive value for osteomyelitis and is commonly tested.

04Management and Treatment

Acute management centers entirely on immobilization and offloading. The total contact cast is the single most important intervention in the acute phase. The principle is simple: if the patient cannot feel damage occurring, you must physically prevent it. The TCC distributes plantar pressure evenly across the entire sole and prevents continued ambulation on a collapsing skeleton. Casting is continued until the acute inflammatory process resolves, which is monitored by serial skin temperature measurements. When the affected foot's temperature comes within 2 degrees Celsius of the contralateral foot and remains stable for at least 2 to 4 consecutive weeks, the acute phase is considered resolved.

There is no pharmacologic therapy that is standard of care for stopping the acute destructive process. Bisphosphonates (such as alendronate or pamidronate) have been studied to reduce osteoclast-mediated bone resorption, but evidence is insufficient to recommend routine use. They may be considered on a case-by-case basis.

Long-term management after the acute phase resolves involves lifelong use of protective footwear. Patients with residual deformity (which is the majority) require custom-molded shoes or a CROW boot. The goal is to accommodate the altered foot architecture and prevent ulceration over bony prominences. Any ulceration in a Charcot foot must be aggressively managed because the risk of secondary osteomyelitis and eventual amputation is high.

Surgical intervention is indicated when the deformity is so severe that bracing cannot prevent ulceration or the foot is grossly unstable. The procedure of choice is arthrodesis (surgical fusion) of the affected joints, using internal fixation or external frames. Surgery carries higher complication rates in neuropathic patients (hardware failure, non-union, infection), so it is reserved for cases that have failed conservative management.

Contraindications and cautions: Avoid early weight-bearing. The single biggest management error is allowing a patient with acute Charcot foot to continue walking in regular shoes. Peripheral vascular disease must be assessed before casting; a TCC on an ischemic limb can cause pressure necrosis. Always check pedal pulses and consider ankle-brachial index ($\text{ABI}\backslash text\{ABI\}$) before applying a cast.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap on exam questions about Charcot foot is misdiagnosing it as cellulitis or osteomyelitis. The classic vignette will present a diabetic patient with a warm, red, swollen foot, and many students reflexively choose cellulitis because the presentation looks infectious. The critical giveaway is that the patient has minimal or no pain, no systemic signs of infection (no fever, no leukocytosis), and intact skin without an entry wound. A warm, painless, swollen foot in a diabetic with known neuropathy is Charcot until proven otherwise.

The second major trap is the Charcot vs. osteomyelitis distinction. When a vignette adds an ulcer overlying the deformity, students must decide whether the bony changes represent Charcot destruction, superimposed osteomyelitis, or both. The key discriminators are: a positive probe-to-bone test through the ulcer strongly suggests osteomyelitis; markedly elevated inflammatory markers favor infection; and on MRI, a focal pattern contiguous with an ulcer points to osteomyelitis while a diffuse periarticular pattern points to Charcot.

Another tested concept is Stage 0 Charcot, where the clinical signs are present (warmth, swelling) but radiographs are completely normal. The correct next step is MRI, not reassurance. Missing Stage 0 and allowing the patient to continue walking leads to full-blown skeletal collapse.

Finally, the management pearl that gets tested repeatedly: the answer to "what is the next best step" for acute Charcot foot is total contact casting and strict offloading, not antibiotics, not surgery, and not a walking boot. Surgery is a last resort, and antibiotics are only indicated if there is a confirmed superimposed infection. The core competency being tested is recognizing a non-infectious inflammatory bone emergency in a neuropathic patient and understanding that immobilization, not medication, is the primary treatment.